

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ESTABLISHMENT OF ENVIRONMENTAL, SOCIAL AND GOVERNANCE COMMITTEE

The board of directors (the “**Board**”) of Everest Medicines Limited (the “**Company**”) announces that an Environmental, Social and Governance Committee (“**ESG Committee**”) has been established with effect from 28 September 2026.

The ESG Committee shall consist of not less than three members. The Board has appointed Mr. Yifang Wu, Mr. Yongqing Luo, Ms. Yue Wang and Mr. Yifan Li as the members of the ESG Committee. Mr. Yifang Wu has also been appointed as the chairman of the ESG Committee.

The terms of reference for the ESG Committee will be published on the website of The Stock Exchange of Hong Kong Limited and the website of the Company.

By Order of the Board
Everest Medicines Limited
Yifang Wu
Chairman and Executive Director

Hong Kong, 28 September 2026

As at the date of this announcement, the Board comprises Mr. Yifang Wu as Chairman and Executive Director, Mr. Yongqing Luo and Mr. Ian Ying Woo as Executive Directors, Mr. Wei Fu, Mr. Xin Sun and Ms. Yue Wang as Non-executive Directors, and Ms. Hoi Yam Chui, Mr. Yifan Li and Mr. Shidong Jiang as Independent Non-executive Directors.